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ABSTRACT  
Diabetes mellitus is a rapidly growing major health problem world-wide. The management of type 2 diabetes mellitus is complex, requiring 
continuous medical care by health care professionals and considerable self-care efforts by patients. A collaborative and integrated team 
approach in which pharmacists can play a pivotal role should be sought when managing patients with diabetes. Pharmacist-led care programs 
have been shown to help patients with diabetes succeed in achieving treatment goals and improving outcomes. Hence, the aim of this narrative 
review is to address and summarize the effectiveness of pharmacist interventions in the management of diabetic patients. A co mprehensive 
literature search was conducted in PubMed/Medline, Scopus, web of Science and the Cochrane Library were searched from the date of database 
inception to June 2019. All randomized controlled trials evaluating the effectiveness of pharmacist-based interventions on diabetic patients in 
comparison with usual care were included in study. Outcomes of interest included short-term and long-term measures such as glycated 
haemoglobin (HbA1c), and secondary outcomes were blood glucose level, blood pressure (BP), lipid profile, body mass index (BMI), 10-year 
coronary heart disease (CHD) risk, medication adherence, health related quality of life (HRQoL), and economic outcomes. Twenty-five studies 
were included in this systematic study. They were heterogeneous in terms of interventions, participants, settings and outcomes. Pharmacist-led 
self-management interventions included education on diabetes and its complications, medication adherence, lifestyle and education of self-
management skills. Few studies even focussed on patients need through a tailored intervention. We found that those who receiv ed the 
pharmacist care had a statistically significant improvement in HbA1C, blood pressure, lipid profile, health-related quality of life, and CHD risk. 
These results underline the added value of pharmacists in patient-related care.  Hence this review supports the involvement of pharmacists as a 
member of health- care teams in managing diabetic patients at diverse settings worldwide.  
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INTRODUCTION 
Diabetes mellitus is a major chronic health problem for 
decades to come. Indeed, it was estimated that 463 million 
people globally suffered from diabetes   in 2019, and this 
number is predicted to increase to 700 million people by 
2045.1 Diabetes, if left uncontrolled, may cause 
microvascular and macrovascular complications in the long 
term, which are the main causes of increased morbidity and 
mortality and decreased health-related quality of life among 
patients.2 
The management of diabetic mellitus is very difficult and it 
became a persisted task all over the world.3 Overtime, 
several studies have shown that prolonged high levels of 
glcaemia lead to micro- and macrovascular complications.4 
The overall goal of diabetes treatment is, therefore, to 
reduce the risk of diabetes-related complications by 
achieving and maintaining near normal glycaemic control 
with lifestyle changes and drug therapy5. Despite the 
benefits of effective therapies, literature demonstrates that 
achievement of desired therapeutic outcomes in patients 
with diabetes remains suboptimal that could increase the 
disease burden.6,7 Barriers to adherence may consists of 
complex treatment regimens, medication side effects, poor 
patient-provider communication, socio-economic issues, 
memory impairment psychological well-being and personal 
beliefs.8 
Due to the complexities associated with managing diabetes 
population, new models of health care delivery should be 
developed and implemented for better glycaemic control.9,10 
Thus, evidences has shown that a multidisciplinary team 
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with collaboration among different healthcare professionals 
can provide a more holistic treatment and to obtain better 
outcomes.11 A larger role of the pharmacist, in diabetes 
treatment by helping patients improve their chances of 
reaching therapeutic and lifestyle goals. The responsibilities 
of pharmacist involve patient education, monitoring 
treatment goals, adherence, drug-related problem 
assessment.12 They can positively influence patients 
individually or with other health professionals in improving 
diabetes management by providing pharmaceutical care 
programs and prudent pharmacological therapy to improve 
disease state outcomes.13 Several studies have 
recommended the involvement of a pharmacist in a diabetes 
multidisciplinary healthcare team including those by the 
American Diabetes Association and Canadian Diabetes 
Association.12,14 Previous literature reviews have proven 
that the contribution of pharmacists in achieving better 
control of diabetes is significant15-16.These reviews focused 
on many types of pharmacist interventions including self-
care related interventions, adherence, and compliance or on 
counselling but always resulted in a significant effect on the 
outcomes of diabetes mellitus17-18. 
In this study, a narrative and systematic review was 
performed to determine the relative efficacy of various 
pharmacist based interventions involving diabetes 
education alone and in combination with pharmaceutical 
care, and those interventions in which diabetes education 
was provided by health care team including pharmacist as 
team member, on clinical outcomes of the type 2 diabetes 
patients. We choose to use glycosylated hemoglobin (HbA1c) 
as primary outcome, as it has been shown to be a good 
surrogate marker for diabetes related complications19. Other 
secondary outcomes include fasting blood sugar (FBS), body 
mass index (BMI), blood pressure control (BP), 
cardiovascular incidences (CV) and lipid profile. 
MATERIALS AND METHODS 
Study design 
 A comprehensive literature search was done in 
PubMed/Medline, Scopus, web of Science and the Cochrane 
Library from the date of database inception to November 
2019. The PubMed search strategy served as a reference for 
the development of search strategies for the remaining 
database. The standardized search strategy included the use 
of medical subject headings terms or text words related to 
pharmacist interventions (pharmacists, pharmaceutical care, 
medication therapy management, pharmaceutical services); 
to the disease (diabetes, diabetes mellitus type2, 
glycosylated haemoglobin, glycaemia, blood glucose, 
glycaemic); and to clinical trials (randomized controlled 
trial, controlled  clinical trial, random allocation). The 
electronic database searches were complemented by 
manually reviewing the reference of relevant reviews and 
included studies. 
Inclusion criteria  
Studies were included in this review if they were 
randomized controlled trials or cluster-randomized 
controlled trials evaluating the effectiveness of interventions 
delivered only or mainly by pharmacists and directed at 
patients with type 2 diabetes in comparison with usual care. 
Studies that took place in a community pharmacy and in 
outpatient primary care and hospital settings were also 
included. Studies were included if they reported one or more 
outcome measures were reported, for example: glycosylated 
haemoglobin (A1c); blood glucose (fasting, postprandial, or 
random); blood pressure; lipid profile (total cholesterol, 
low-density lipoprotein cholesterol [LDL], high-density 
lipoprotein cholesterol [HDL], and triglycerides; body mass 
index (BMI), medication adherence or health-related quality 
of life (HRQoL). It must be an original study published in a 
peer-reviewed journal and the full text article was published 
in English language. 
Study selection 
Two independent reviewers screened all titles and abstracts 
retrieved from the electronic databases using the pre-
defined inclusion criteria. Then, the full text of each 
potentially eligible article was obtained and screened 
independently by two reviewers to determine their 
eligibility for further analysis. Any discrepancies regarding 
study inclusion was resolved through discussion. 
Data extraction and Synthesis 
One of the researchers extracted the data from the studies 
included in this review. No blinding for author or journal 
was applied in the extraction process. The data extracted 
from the studies includes publication details (title, authors, 
publication year and journal name); study design 
characteristics (country where the study took place, type of 
the study, sample size, period of study); study characteristics 
(patients age, gender, follow-up duration, details of 
pharmacist interventions and usual care, inclusion and 
exclusion criteria) and study outcomes. The description of 
the intervention includes counselling on diabetes education, 
quality of life, medication details, lifestyle modifications, 
patient compliance toward the treatment, and clinical 
outcomes (HbA1c, fasting and random blood glucose levels, 
BP, BMI, and lipid profile). Pharmacist interventions were 
evaluated in all the included studies. Outcomes in the form of 
HbA1c, random and fasting glucose levels, BP, BMI, and lipid 
profiles were evaluated in all included studies. The risk of 
bias in the included studies was measured by two 
independent reviewers according to pre-defined criteria 
based on the Cochrane risk-of-bias tool (Rob 2.0). Any 
divergences were deliberated till consensus was reached. 
Results for all the outcomes (HbA1c, FBS, BMI, CV incidence, 
BP, lipid profile etc) and intervention across the included 
studies were analysed and described narratively. 
RESULTS 
In total 5919 articles were identified from the electronic 
database searches. On the basis of title and abstract 
evaluation 3930 studies were excluded as they did not meet 
the inclusion criteria of the study. The full text of 66 papers 
was assessed, with 25 papers finally being included in the 
review. (Figure 1). The main characteristics and study 
population of the included studies are presented in Table 1. 
Study characteristics 
The studies included were heterogenous in terms of 
interventions, participants, settings and outcomes. They 
varied in their quality and reporting of their findings 
conducted in several setting including: standard care, 
pharmaceutical care or family practice in the UK, Spain or 
elsewhere in the world20-28. Among the included studies 24 
were randomised controlled studies20-35,37-44 and one was 
cluster randomised36. All studies were published from 2009 
onwards. Most of the included studies (n = 12) were 
conducted in Asia,22 24 27 28 30 34 35 39 40 41 43 44 followed by 
Europe (n = 5),21 31 33 36 38 North America (n = 5),25 26 29 32 42 
South America (n = 2),23 37 and Africa (n = 1).30  
The median follow-up time was 6 
months,22,23,25,28,30,33,36,37,38,40,41,42,44 two studies had a follow-
up time of less than 6 months27,39 and ten of more than 6 
months.20,21,24,26,29,31,32,34,35,43 
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 The majority of the studies focused primarily on diabetes 
mellitus type 2 patients,20,22-28,30,31,33-44 (n=22), one study 
included both type 1 and type 2 patients,32 and one study did 
not specify the type of diabetes.29 
Description of Intervention 
The settings in which the studies took place included 
community pharmacies, primary care clinics or health 
centres, and hospitals. The nature of interventions provided 
by pharmacist varied among the included studies and 
covered one or more of the following topics:  counselling and 
education on diabetes, medication, lifestyle modification, 
and self-monitoring; reinforcement of medication adherence 
or complications screening; provision of materials such as 
educational leaflets and pill boxes; medication review; 
identification and resolution of drug-related problems; 
discussions with the primary care provider regarding 
pharmacotherapy; adjustment of pharmacotherapy; and 
referrals to other health care professionals. Two studies 
mentioned motivational interviews as a technique used to 
deliver advice to patients.20,28 In most studies, the control 
group received usual care from medical and nursing staff 
and/or community pharmacists, depending on the study 
setting. 
 The intervention in the included studies were all provided 
by a trained pharmacist, either by pharmacist alone20-24,26-
33,35-37,39,40,43,44 or within a multi-disciplinary team.25,34,41,42 
one study did not specify the intervention team, besides 
including a pharmacist.38 Most interventions targeted the 
individual patient20-24,26,28-33,35-40,43,44 whereas some 
interventions used group sessions25,34,41,42. One study did not 
specify whether the intervention was offered in an 
individual or group setting27. 
Thirteen studies included diabetes education as 
interventions21-23,25,28,30,31,36,39-42,44 either about diabetes in 
general or about acute and chronic complications. Patient 
education on medication was provided by the pharmacists in 
16 included studies and this included education about 
adherence, dosage, drug-related problems, indication, 
storage, and use20-29,31,37-40,42,44. 
In eighteen studies the intervention included self-
management skills support20-22,25-27,29-32,34,38-44 and in around 
10 studies participants were trained in self-monitoring 
glucose.22,23,25,28,30-32,39,40,42 
In most of the studies, education was given on lifestyle 
modifications, exercise requirements, foot cares, 
management of proper diet and smoking cessation were 
included as the part of the intervention by the pharmacists. 
Other interventions such as the use of a diabetes diary and 
provision of written educational material were reported in 
the included studies. 
  
 
 
 
 
 
 
 
 
             
             
             
             
             
          
             
             
             
             
             
                                                    Figure 1: Flow chart of study selection 
 
DISCUSSION  
This review found evidence of the importance of the clinical 
pharmacist/ pharmacist care program that targeted 
immediate and long-term risk factors associated with 
diabetes mellitus. This extended across multiple health care 
settings and cultures worldwide. In most of the included 
studies, pharmacist’s role was mainly to specify all drug 
related problem including poor drug compliance and side 
effects and communicating these to the physician. such 
rapport is crucial in building professional working relations 
necessary to ensure optimal patient care. However, 
pharmacist involvement is not meant to replace the formal 
diabetes education or physician direct care, nevertheless, the 
program provides a usual supplement or enhancement to the 
care of diabetic patients. 
The type, intensity, and frequency of the interventions were 
different in all the included studies. The number of visits for 
face-to-face interactions varied once in a week to once in 
a year. Some of the included studies do have face-to face 
contact with the pharmacists or pharmacy 
departments20,22,35 and some have combination of face to-
face contacts along with telephone contact with the 
pharmacists or department of pharmacy. 25,28 The evidence 
indicate that telephone interventions are effective and 
significant improvement in glycaemic level.45  
Studies identified by database searches                                          
N = 5919 
 
Duplicate studies are excluded 
N = 3996 
 
Total title and abstract screened                          
N = 3996 
full-text articles assessed for eligibility                                                             
N =66 
 
studies included                                                                                  
N = 25 
full-text articles excluded                                                             
N = 41 
Irrelevant records removed                                                             
N =3930 
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Table No.1: Characteristics of the included studies. 
Author, Year, 
Country 
 
Study design No. of Patients 
Lost to Follow-up 
Age in Years (Mean 
[SD]) 
Gender (%) 
Follow-
up 
Duration 
Pharmacist 
Intervention 
Control Outcome 
measure 
Adibe et al. 
201 320 
Nigeria 
Randomized, 
controlled 
study 
No. of patients 
(IG/CG):110/110  
Lost to follow-up 
(IG/CG):11/17  
Age (IG/CG): 
52.4[7.6]/52.8 [8.2]  
Gender (IG/CG): 
44.6%/40.0% male 
12 months Pharmaceutical care 
including education on 
diabetes, self-monitoring, 
medication, lifestyle 
modification, counselling, 
and effective interaction 
with health providers 
Usual care 
offered by 
hospitals 
HbA1c. LDL, 
CVD risks, 
HRQoL, 
medication 
understanding, 
cost-utility 
analysis 
Ali et al. 
2012 
UK 21 
Randomized, 
controlled 
study 
No. of patients 
(IG/CG):25/23 
 Lost to follow-up 
(IG/CG): 2/0 
 Age (IG/CG): 
66.4[12.7]/66.8 [10.2]  
Gender (IG/CG): 
43.5%/56.5% male 
12 months Pharmaceutical care 
including medicine use 
review; education 
regarding diabetes and its 
complications; and 
counselling on lifestyle 
modification with referral 
to other health care 
professional when 
appropriate 
Usual 
service 
from 
general 
practition
er, 
practice 
nurse, and 
communit
y 
pharmacy 
A1c, BG, SBP, 
DBP, TC, LDL, 
HDL, TG, BMI, 
DQoL, HRQoL, 
diabetes 
knowledge, 
SIMS, beliefs 
about 
medicines, 
other 
Butt et al. 
2016 22 
Malaysia  
Randomized, 
controlled 
study 
No. of Patients 
(IG/CG):33/33 
Lost to follow-up 
(IG/CG):4/3 
Age (IG/CG) 57.42 
[7.17]/57.12[10.78] 
Gender (IG/CG): 
60.6/57.6   
6 months Pharmaceutical care 
including education on 
diabetes and its 
complication, self-
management education, 
counselling on medication 
use and medication 
adherence 
Usual care HbA1c, FBS, 
BMI, TC, HDL-C, 
LDL- C, 
triglycerides, 
QoL, diabetes 
education and 
MMMAS scores 
Cani et al 
2015 23 
Brazil  
Parallel 
randomized 
controlled 
trial 
No. of Patients 
(IG/CG):37/41  
Lost to follow-up 
(IG/CG):3/5  
Age(IG/CG): 
61.91(9.58)/61.58(8.14)  
Gender 
(IG/CG):61.7/61.1  
6 months Individualized 
pharmacotherapeutic 
care plan consisting of 
education about diabetes, 
education on lifestyle 
modification and 
provision of free 
glucometer and pill 
counter 
Standard 
care 
HbA1c, FBS, 
BMI, QoL, 
medication 
adherence, 
insulin injection 
and home blood 
glucose 
monitoring 
techniques, 
diabetes 
education 
Chan et al. 
2012 24 
Hong Kong 
Parallel 
randomized 
controlled 
trial 
No. of Patients 
(IG/CG):51/54 
Lost to follow-up 
(IG/CG):0/0 
 Age (IG/CG): 
63.2(9.5)/61.7(11.2)  
Gender (IG/CG) 
female(%): 41.2/48.1 
9 months Pharmaceutical care 
program addressing 
medication adherence, 
knowledge and beliefs, 
skills, perceived health 
and cognitive functions, 
and identification of DRPs 
Routine 
medical 
care 
HbA1c, SBP, 
DBP, TC, LDL, 
HDL, TG, BMI, 
Albumin-
creatinine ratio, 
CHD risk, stroke 
risk medication 
knowledge, 
medication 
adherence, cost-
effectiveness 
analysis 
Cohen et al. 
201125 
USA 
Randomized 
controlled 
trial 
No. of patients 
(IG/CG):53/50 
 Lost to follow-up 
(IG/CG): 5/2  
Age (IG/CG): 
6 months  Part of a multidisciplinary 
diabetes specific healthy 
lifestyle education 
intervention and 
behavioural and 
pharmacologic 
interventions, including 
Standard 
primary 
care 
HbA1c, SBP, 
LDL, HRQoL, 
perceived 
competence, 
adherence to 
self-care 
activities, 
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69.8[10.7]/67.2 [9.4]  
Gender (IG/CG): 
100.0/96.0 % male 
medication changes disease 
knowledge 
Doucette et 
al. 2009 26 
USA 
Parallel 
randomised 
controlled 
trial 
No. of Patients 
(IG/CG):36/42 
 Lost to follow-up 
(IG/CG):5/7 
Age (IG/CG): 
58.7(13.3)/61.2(10.9)  
Gender (IG/CG): 
61.8/53.7 % male 
12 months Pharmaceutical care 
including education on 
diabetes, self-monitoring 
and pharmacologic 
interventions including 
medication changes 
Standard 
primary 
care 
 
HbA1c, BP, LDL-
C, adherence to 
self-care 
activities 
 
Farsaei et al  
201127 
Iran 
Parallel 
randomized 
controlled 
study  
No. of patients 
(IG/CG):87/87 
Lost to follow-up: NR 
Age (IG/CG): 
53.4[9.8]/52.9 [8.5]  
Gender(IG/CG): 
63.2%/68.2% female 
3 months Pharmacist-led program 
including education on 
medications adherence 
and self-management and 
provision of SMBG data 
entry log book 
General 
education 
offered by 
the 
nursing 
staff 
HbA1c, FBG 
Jarab et al 
2012 28 
Jordan  
Parallel 
randomized 
controlled 
study 
No. of patients 
(IG/CG):85/86 
Lost to follow-up 
(IG/CG):8/7 
Age (IG/CG): 63.4 
[10.1]/65.3 [9.2]  
Gender (IG/CG): 
42.4/44.2 % female 
6 months Comprehensive clinical 
pharmacy care including 
education on diabetes, 
medication and lifestyle 
changes; review of 
prescribed treatment; 
referral to a smoking 
cessation program; and 
provision of booklet 
about diabetes 
medications and lifestyle 
changes 
Usual care HbA1c, FBS, BP, 
lipid levels BMI, 
diabetes self-
care activities, 
medication 
adherence 
Jameson et 
al 
2010 29 
USA 
Parallel 
randomized 
controlled 
study 
No. of Patients 
(IG/CG):52/51 
Lost to follow-up (IG/CG): 
not mentioned 
Age (IG/CG): 
49.3(10.8)/49.7(10.9) 
Gender (IG/CG): 
]51.1/5% female 
12 months Evaluation and 
adjustment of therapeutic 
regimen, and patient 
education on self -care 
activities, medication and 
insulin, and medication 
adherence  
Usual care HbA1c 
Jahangard-
Rafsanjani et 
al.  
2015 30 
Iran 
Parallel 
randomized 
controlled 
study 
No. of Patients 
(IG/CG):51/50 
Lost to follow-up 
(IG/CG):6/10 
Age (IG/CG): 
57.3(8.6)/55.9(8.7)  
Gender (IG/CG): 
49/52%Female 
6 months  Pharmaceutical care 
involving education about 
diabetes and its 
complication and on self-
management, counselling 
on medication adherence, 
provision of written 
educational material and 
SMBG data entry log book   
Usual care  HbA1c, BP, 
Medication 
adherence, 
Diabetes self-
care activity, 
BMI, 
satisfaction, 
diabetes 
knowledge  
   
Korcegez et 
al.  
2017 31 
Cyprus  
Parallel 
randomized 
controlled 
study 
No. of Patients 
(IG/CG):79/80 
Lost to follow-up 
(IG/CG):4/3 
Age(IG/CG): 
61.80±10.38/62.22±9.54 
Gender (IG/CG) 
female(%):77.3/74 
12 months Pharmaceutical care 
including education about 
diabetes and its 
complication, self-
management and on 
lifestyle modification, 
counselling for 
medication use, provision 
of written educational 
material  
Usual care HbA1c, FBS, 
SBP, DBP, TC, 
LDL-C, HDL-C, 
TGs, BMI, 
Medication 
adherences, 
diabetes 
knowledge, self- 
care activities 
Kraemer et 
al. 2012 32 
USA 
Parallel 
randomized 
controlled 
study 
No. of Patients 
(IG/CG):36/31 
Lost to follow-up 
12 months pharmacist counselling 
and empowering with 
diabetes education and its 
complication, self-
management and on 
Usual care 
with 
written 
education
al 
HbA1c, FBS, 
SBP, DBP, TC, 
LDL-C, HDL-C, 
TGs, BMI 
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(IG/CG):1/1 
Age(IG/CG): 
55.6(6.8)/52.6 (9.2) 
Gender (IG/CG) 
female(%): 38.8/61.29 
lifestyle modification, 
medication use, provision 
of written educational 
material 
informatio
n about 
managing 
diabetes 
Kjeldsen et 
al. 2015 33 
Denmark  
Randomized 
controlled 
study 
No. of patients 
(IG/CG):41/125  
Lost to follow-up 
(IG/CG):4/23  
Age (IG/CG): 63.4 
[7.8]/62.1 [10.2]  
Gender (IG/CG): 
59.5/62.4% male 
6 months Pharmaceutical care by 
nonadherence screening, 
medication review, 
patient education and 
coaching regarding 
metabolic syndrome, 
support to structure and 
remember medication 
intake, feedback to PCP, 
and referral to other 
health services 
NR BG, SBP, HRQoL, 
disease 
knowledge, 
medication 
adherence, 
patient 
satisfaction with 
service, others 
Lau et al. 
2018 34 
Malaysia 
Pilot 
retrospective 
cohort study 
No. of Patients 
(IG/CG):29/29 
Lost to follow-up 
(IG/CG):0/0 
Age (IG/CG): 54.24 
(9.97)/ 59.07 (10.25)  
Gender (IG/CG): 
48.1/51.9 % female 
12 months Multidisciplinary 
collaborative care by 
educating patients 
regarding diabetes 
control, nutrition 
restriction and 
requirement, 
management of co-
morbid conditions, and 
lifestyle modification. 
medication adjustment, 
Standard 
primary 
care 
HbA1c, diabetic 
related 
hospitalization 
Lim et al.  
2016 35 
Malaysia 
Prospective 
randomized 
open-labelled 
study 
No. of Patients 
(IG/CG):50/50 
Lost to follow-up 
(IG/CG):11/13 
Age (IG/CG): 
55.62(1.49)/57.00(1.56) 
Gender(IG/CG): 
53.8/54.1 % female 
12 months Education regarding life 
style modification, 
diabetes and its 
complication, counselling 
for medication use and 
medication adherence 
and provision of written 
educational material 
Usual care HbA1c, FBG, 
BMI, SBP, DBP 
Mehuys et al 
2011 36 
Belgium  
Cluster 
randomized 
controlled 
study 
No. of Patients 
(IG/CG):153/135 
Lost to follow-up 
(IG/CG):5/3 
Age (IG/CG): 63.0(40–
84)/62.3(45–79) 
Gender (IG/CG) 
female(%):49/46.3 
6 months Education on diabetes 
and its complications, 
medication and healthy 
lifestyles, facilitation of 
medication adherence, 
and reminders about 
annual eye and foot 
examinations 
Usual 
pharmacis
t care 
HbA1c, FBG, 
medication 
adherence, 
diabetes 
knowledge, 
adherence to 
self-care 
activities 
Mourao et al 
2013 37 
Brazil 
 
Parallel 
randomized 
controlled 
study 
No. of patients 
(IG/CG):65/64  
Lost to follow-up 
(IG/CG):12/9  
Age (IG/CG): 
60.0[10.2]/61.3 [9.9]  
Gender (IG/CG): 
68.0%/66.0% female 
6 months Pharmaceutical care, 
providing patient 
education about diabetes; 
non pharmacological 
issues, and 
pharmacological 
treatments proposals for 
pharmacotherapy 
changes forwarded to 
PCP;  
Usual 
health 
care 
HbA1c, FBG, 
SBP, DBP, TC, 
LDL, HDL, TG, 
BMI, medication 
use, 
Nascimento 
et al  
2016 38 
Portugal  
Parallel 
randomized 
controlled 
study 
No. of Patients 
(IG/CG):44/43 
Lost to follow-up 
(IG/CG):0/0 
Age (IG/CG): 
74.2(5.4)/72.3(4.5) 
Gender(IG/CG): 
43.2/41.9 %female 
6 months Individualized 
pharmacotherapy 
management service 
including education about 
diabetes and its 
complication and 
medication use, self- 
management skills 
NR HbA1c, FBG, 
medication 
adherence, 
adherence to 
self-care 
activities 
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Samtia et al 
2013 39 
Pakistan 
 
Parallel 
randomized 
controlled 
study 
No. of Patients (IG/CG): 
46.1(23-74)/42.3(21–77) 
Lost to follow-up 
(IG/CG):4/2  
Age (IG/CG): 
54(13)/57(11) 
Gender (IG/CG): 
47.2/51.2 %female 
5 months Multifactorial 
Intervention consisting of 
education on diabetes, 
medication use and 
lifestyle modification, 
counselling for 
medication adherence 
and SMBG education 
NR HbA1c, FBG, 
BMI, medication 
adherence, 
Diabetes 
knowledge 
Shao et al 
2017 40 
China 
 
Parallel 
randomized 
controlled 
study 
No. of Patients 
(IG/CG):120/120 
Lost to follow-up 
(IG/CG):20/21 
Age (IG/CG): 58.86 
±10.59/59.20±10.34 
Gender (IG/CG): 
49/42.5%female 
6 months Pharmaceutical care 
including education on 
diabetes and its 
complications, medication 
and healthy lifestyles, and 
also on self-management 
skills 
Usual care HbA1c, FBS, 
SBP, DBP, TC, 
LDL-C, HDL-C, 
TGs, BMI, 
Medication 
adherences, 
self- care 
activities 
Siaw et al  
2017 41 
Singapore 
 
Parallel 
randomized 
controlled 
study 
No. of Patients 
(IG/CG):214/197  
Lost to follow-up 
(IG/CG):0/0 
Age (IG/CG): 
59.2±8.2/60.1±8.1 
Gender (IG/CG): 
47.7/39.1% female 
6 months Multidisciplinary 
collaborative care 
including education on 
diabetes and its 
complications, and on 
self-management skills 
Usual care HbA1c, cost-
effective 
analysis 
Taveira et al 
2010 42 
USA 
Parallel 
randomized 
controlled 
study 
No. of Patients 
(IG/CG):64/54 
Lost to follow-up 
(IG/CG):6/3 
Age (IG/CG):62.2 
(10.3)/66.8(10.2)  
Gender (IG/CG) 
female(%): 8.6/0 
6 months Part of multidisciplinary 
education intervention 
regarding self-care 
behaviours and 
behavioural and 
pharmacological 
interventions, including 
medication change 
Usual care HbA1c, SBP, 
DBP, LDL, non-
HDL, BMI, 
tobacco use, 
CHD risk factor, 
adherence to 
self-care 
behaviours 
Tourkmani 
et al  
2016 43 
Saudi Arabia 
Parallel 
randomized 
controlled 
study 
No. of Patients 
(IG/CG):140/122 
Lost to follow-up 
(IG/CG):73/8  
Age (IG/CG): 55.12 
(12.76)/56.06 (11.08) 
 Gender (IG/CG):60/66.4 
9 months Education program on 
diabetes and its 
complications, medication 
and healthy lifestyles, and 
also on self-management 
skills, provision of written 
educational material  
Standard 
diabetic 
care 
HbA1c, SBP, 
DBP, LDL, HDL, 
TC, TG BMI,  
Wishah et al 
2015 44 
Jordan 
 
Parallel 
randomized 
controlled 
study 
No. of patients 
(IG/CG):52/54  
Lost to follow-up 
(IG/CG):2/3  
Age (IG/CG): 
52.9[9.6]/53.2 [11.2]  
Gender (IG/CG): 
61.5%/51.9% female 
6 months Pharmaceutical care, 
including optimization of 
drug therapy; education 
and counselling on 
diabetes and medication; 
enhancement of 
adherence to medication 
and self-care activities; 
and provision of 
educational leaflet and 
brochures 
Usual care 
provided 
by the 
medical 
and 
nursing 
staff 
HbA1c, FBG, TC, 
LDL, HDL, TG, 
BMI, diabetes 
knowledge, 
medication 
adherence, 
diabetes self-
care activities 
IG – intervention group; CG -control group; HRQoL- health related quality of life; BG-blood glucose; SBP - systolic blood pressure; DBP- diastolic 
blood pressure; TC – total cholesterol; LDL – low-density lipoprotein cholesterol; HDL – high- density lipoprotein cholesterol; TG – 
triglycerides; BMI – body mass index; DQoL – diabetic quality of life; SIMS – satisfaction of information received about medicines; FBG – fasting 
blood glucose 
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Various guidelines for diabetes recommend that a target 
HbA1c of a diabetic patient should be 7% or less. In order to 
decrease the chances of diabetic complication in those 
patients who have HbA1c more than 7%, it is recommended 
to reduce the HbA1c up to 1% or more. Thus, a tight control 
of FBS and random blood sugar (RBS) is needed to decrease 
diabetes complications.17 Thus, pharmacist intervention is 
needed to reduce the FBS and RBS of patients as shown in 
the included studies of analysis.  HbA1c was considered as an 
outcome measure in 24 studies. A1c mean value decreased in 
the intervention group during the follow-up period in all 
studies. Further analysis revealed that larger effect was 
made by studies which involved pharmacist-based diabetes 
education, followed by studies which involved pharmacist-
based diabetes education plus pharmaceutical care and 
studies in which diabetes education was provided by health 
care team involving pharmacist.46 
Regarding the blood pressure, in this review it reveals that in 
comparison with the control, 11 out of 13 studies 
demonstrated a significant reduction in the blood pressure in 
the intervention group21,25,28,30-33,35,37,40,42,43,44. The American 
Association of Clinical Endocrinologists and American 
College of Endocrinology CPGs on diabetes recommends that 
the target BP of diabetics should be less than 140/80–90 mm 
Hg to decrease the risk of microvascular and macrovascular 
complications.23 According to Indian guidelines, currently 
recommend the standard BP target of <140 mm systolic and 
< 90 mm in patients with diabetes to decrease the chances of 
complications. 
Ten studies described total cholesterol as an outcome 
measure21,22,24,28,31,32,37.40,43,44. In all of these studies, there 
was a reduction in the intervention group from baseline to 
final follow up, and seven studies reported a greater 
improvement in this outcome in comparison with the control 
group. Regarding LDL cholesterol, 14 studies reported data 
on this outcome, and all of them demonstrated a decrease in 
the intervention group from baseline to final follow-up20-22,24-
26,28,31,32,37.40,42-44. Ten studies reported a greater reduction in 
this outcome in the intervention group compared with the 
control group. Among the 11 studies that reported HDL 
cholesterol as an outcome measure, 10 studies described an 
increase in the intervention group from baseline to final 
follow-up21,22,24,31,32,37,40,42,43,44 and one study observed a 
decrease in the parameter28. Guidelines of various countries 
such as Australia, UK, USA, and Malaysia strongly 
recommend the use of a lipid-profile control medication such 
as a statin if it is not contraindicated to decrease the risk of 
cardiovascular disease (CVD) development17. Although the 
chances of development of diabetes with statin use are 
reported,47,48 many meta-analyses on randomized trials 
reported the advantages of statins to decrease the CV 
risks.17,49 
Fifteen studies described BMI as an outcome measure, in all 
studies mean BMI decreased in the intervention group from 
baseline to final follow-up.21-24,28,30-32,35, 37, 39,40, 42-44 
CHD risk was predicted among five of the included studies in 
diabetic patients20, 24,31,39,42. The method used to estimate this 
risk varied between studies. All 5 studies recorded a 
decrease in CHD risk in the intervention group from baseline 
to final follow-up and reported a greater improvement in this 
group compared with the control group. Two studies used 
the United Kingdom Prospective Diabetes Study (UKPDS) 
risk engine, 31, 42 Two studies used the Framingham 
prediction method20,39, and one study used an equation 
specifically validated for the Hong Kong population24. All the 
models incorporated the variables age, sex, and smoking 
status6.the equation validated for the Hong Kong population 
also includes the duration of diabetes24. while the 
Framingham prediction model considers the presence or 
absence of diabetes as a variable.50 In addition to the 
duration of diabetes, the UKPDS risk engine also 
incorporates the A1c mean values. Regarding blood pressure, 
the UKPDS risk engine and the British National Formulary 
prediction charts include systolic blood pressure, while the 
Framingham prediction model integrates systolic and 
diastolic blood pressure. As for the lipid profile, the UKPDS 
risk engine and the British National Formulary prediction 
charts consider the total cholesterol/HDL cholesterol ratio as 
a variable, while the Framingham prediction model only 
includes HDL cholesterol, and the equation validated for the 
Hong Kong population incorporates non-HDL cholesterol. In 
addition to the previously mentioned variables, the UKPDS 
risk engine also considers ethnicity as a variable, and the 
equation validated for the Hong Kong population integrates 
glomerular filtration rate and urinary albumin to creatinine 
ratio.6 
Adherence to medications was measured in 12 studies22-
24,28,30,31,33,36,38,39,40,44. The methods used to measure this 
outcome varied between the studies. Self-reported 
adherence was used to measure this outcome almost in all 
studies, while one study used pill count or prescription refill 
rate in combination with self-reported adherence36. Eleven 
studies revealed an improvement in medication adherence in 
the intervention group from baseline to final follow-up. 
Health-Related Quality of life was measured in six studies.20-
23.25,33 Five studies used the validated EuroQol-5 Dimension 
questionnaire which can be applied in different health 
conditions and diseases and one study used generic and 
diabetes-specific tools21 to measure this outcome. All studies 
reported an improvement in HRQoL in the intervention 
group from baseline to final follow-up, which was greater 
than that observed in the control group. 
The evidence regarding the cost-effectiveness of pharmacist 
interventions was limited. In fact, only 3 studies conducted 
an economic analysis. Chan et al. (2012) estimated the cost-
effectiveness of the pharmacist care program being studied 
based on CHD risk reduction and the direct cost of time spent 
by the pharmacist in counselling and associated 
administrative work.24The estimated potential saving in 
costs was $5,086.30 USD per patient.24 Adibe et al. (2013) 
conducted a cost-utility analysis of the pharmaceutical care 
intervention implemented.20 The total cost per patient per 
year was $326.00 USD for the control group and $394.00 
USD for the intervention group.20 Siaw et al. (2017) also 
conducted a cost-effectiveness analysis for the pharmacist 
intervention being studied.41The 6-month mean cost  for 
direct outpatient diabetes- related care was US$516.77 for 
the intervention arm and US$607.78 for the control arm (p < 
.001).  Compared to the control arm, an average cost savings 
of US$91.01 per patient over 6 months was achieved by the 
intervention arm.41 This is in accordance with the findings 
from the other 2 systematic reviews that evaluated the 
effects of pharmacist interventions on patients with diabetes, 
in which a small proportion of studies assessed the cost-
effectiveness of the interventions under study.6 However, 
given the current resource restraints in the health care 
systems, and in order to inform policymakers and influence 
their decisions towards widespread implementation of 
pharmacist interventions on the management of type 2 
diabetes, cost-utility studies proving the cost-effectiveness of 
such interventions are of the utmost importance. Indeed, a 
comprehensive evaluation of pharmaceutical services has to 
consider clinical and humanistic outcomes, as well as 
economic outcomes.51 
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CONCLUSION 
This review demonstrates a comprehensive evidence on the 
pharmacist-led interventions is associated with better 
glycaemic control and medication adherence. This narrative 
review supports a potential role of the pharmacists in 
diabetic care to help and support other healthcare 
professionals to achieve the target therapy outcomes. 
Therefore, they are very valuable to the care of such patients 
and should be considered and involved in diabetes care to 
help patients more effectively control their disease. 
Overall, our review revealed that the pharmacist-led group 
intervention program was an efficacious and sustainable 
collaborative care approach to manage diabetes, self-
management interventions and reduce associated 
cardiovascular risk. 
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